Buoyed By Lunesta, Sepracor To Boost Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will hire 500 additional reps by May, just before rival Pfizer/Neurocrine’s indiplon user fee date.
You may also be interested in...
Lunesta’s Expanded Sales Force Will Focus On Maintenance Use
Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.
Lunesta’s Expanded Sales Force Will Focus On Maintenance Use
Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.
Indiplon Driving Study Could Push Marketing Into High Gear
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.